Array BioPharma Inc. (ARRY)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.59-0.02 (-0.30%)
At close: 4:00 PM EDT

6.60 0.01 (0.15%)
Pre-Market: 8:20 AM EDT

People also watch:
ARQLEXELCLDXRIGLARIA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open7.22
Prev Close6.61
Bid6.68 x 900
Ask6.69 x 1700
Day's Range6.30 - 7.27
52wk Range2.38 - 7.27
1y Target EstN/A
Market Cap955.7M
P/E Ratio (ttm)-10.14
Beta1.14
Volume50,298,594
Avg Vol (3m)4,287,810
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire11 hours ago

    Array BioPharma Announces Pricing of Public Offering of Common Stock

    Array also granted the underwriters a 30-day option to purchase up to 2,760,000 additional shares of common stock. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.  Stifel and Wells Fargo Securities, LLC are acting as lead managers and SunTrust Robinson Humphrey, Inc. is acting as co-manager. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, Attn: Prospectus Department, telephone: 631-274-2806.

  • 3 Reasons to Buy Array Biopharma
    Motley Fool14 hours ago

    3 Reasons to Buy Array Biopharma

    Upcoming catalysts including a FDA decision on its melanoma medicine could help shares move higher.

  • PR Newswire16 hours ago

    Array BioPharma Announces Proposed Public Offering of Common Stock

    BOULDER, Colo., Sept. 27, 2016 /PRNewswire/ -- Array BioPharma (ARRY) today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma.